Vistagen Therapeutics Inc (VTGN) USD0.001
Sell:$2.50Buy:$3.00
$0.07
(2.45%)
- This stock can be held in a
Stocks and Shares ISA$0.07
(2.45%)$0.07
(2.45%)Company Information
About this company
Vistagen Therapeutics, Inc. is a neuroscience-focused biopharmaceutical company. The Company is engaged in the development and commercialization of therapies for psychiatric and neurological disorders based on its understanding of nose-to-brain neurocircuitry. Its clinical-stage pipeline consists of intranasal product candidates from a new class of potential neuroscience therapies called pherines. Its diversified pipeline of pherine product candidates rapidly activate chemosensory neurons in the nasal cavity to impact fundamental neurocircuitry in the olfactory system and the brain. Its pipeline also includes an oral prodrug with potential to modulate N-methyl-D-aspartate receptor (NMDA) receptor activity. Its neuroscience pipeline includes five clinical-stage investigational agent, namely Fasedienol (PH94B), Itruvone (PH10), AV-101, PH15, PH80, and PH284.
Key people
Key facts
- EPICVTGN
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS92840H4002
- Market cap$79.66m
- Employees48
- Shares in issue28.87m
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.